医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024

2024年07月10日 PM08:30
このエントリーをはてなブックマークに追加


 

SHANGHAI, China & CAMBRIDGE, Mass.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the second quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Tuesday, August 6, 2024. The Company will host a live conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET (8:00 p.m. HKT).

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company’s website at http://ir.zailaboratory.com. Participants must register in advance of the conference call.

Details are as follows:

Registration Link: https://register.vevent.com/register/BIaccafead4b094cf191720bf5d03048c6

All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.

A replay will be available shortly after the call and can be accessed by visiting the Company’s website.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710676842/en/

CONTACT

Investor Relations:

Christine Chiou / Lina Zhang

+1 (917) 886-6929 / +86 136 8257 6943

christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com

Media:

Shaun Maccoun / Xiaoyu Chen

+1 (415) 317-7255 / +86 185 0015 5011

shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

同じカテゴリーの記事 

  • GC Aesthetics®推出YOUTHLY™:中国乳房植体进入新时代
  • Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy
  • Neuraptive Therapeutics宣布在2024年美国手外科学会(ASSH)年会上公布NTX-001的2期顶线中期结果
  • ニューラプティブ・セラピューティック、NTX-001の第2相トップライン中間結果を2024年米国手外科学会(ASSH)年次総会でプレゼンテーションすると発表
  • オルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®(タピナロフ)クリーム1%を取得